Overview
NVCR market data
Price History
NVCR price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.22 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.97 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $9.82 – $20.55 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $2.3K · P/B 4.25 · P/S 3.40.
Company news
NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From SlidingBenzinga · Jul 24, 2026, 3:08 PM
Wedbush Maintains Neutral on NovoCure, Raises Price Target to $20Benzinga · Jul 24, 2026, 12:51 PM
HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $52Benzinga · Jul 23, 2026, 5:50 PM
Crude Oil Rises Sharply; T-Mobile Shares Fall Following Q2 ResultsBenzinga · Jul 23, 2026, 5:31 PM
12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga · Jul 23, 2026, 5:05 PM
Lockheed Martin, Quest Diagnostics, Thermo Fisher Scientific And Other Big Stocks Moving Higher On ThursdayBenzinga · Jul 23, 2026, 2:20 PM
NovoCure shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.Benzinga · Jul 23, 2026, 1:30 PM
Transcript: NovoCure Q2 2026 Earnings Conference CallBenzinga · Jul 23, 2026, 1:07 PM
Earnings Scheduled For July 23, 2026Benzinga · Jul 23, 2026, 11:11 AM
NovoCure Raises FY2026 Sales Guidance from $690.000M-$710.000M to $710.000M-$725.000M vs $708.743M EstBenzinga · Jul 23, 2026, 11:01 AM